Michael Dunlop achieved the extraordinary feat of winning his 30th TT in the Monster Energy Supersport TT on Monday at the ...

For each 5-mg/dL increase in serum TTR level within 28 days of starting ... recurrent CVH events relative to placebo at Month 30 - A 50% reduction in the cumulative frequency of CVH events ...

(MENAFN- GlobeNewsWire - Nasdaq) - For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment ... ACM and recurrent CVH events relative to placebo at Month 30 - A 50% reduction ...

Intellia reports positive two-year results for nex-z, showing significant TTR reductions and improved ATTRv-PN outcomes without new safety concerns. Intellia Therapeutics announced positive two ...

A company's plan to mine 50 million tonnes of South Taranaki seabed every year has cleared the first hurdle in the Fast-track process.

50 If a TTR gene variant is detected in cases with no family history, a tissue diagnosis is required. Practice varies across countries and with different phenotypical expression, but may include ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) announced its plan to present new data from its transthyretin amyloidosis (TTR) franchise at the Heart Failure 2025 Congress, alongside securing broader ...

The U.S. TTR franchise achieved a 45% year-over-year ... Poulton noted that the current foreign exchange environment could yield approximately $50 million in currency upside if rates remain ...

Front Suspension: Telescopic fork; 3.8-in. travel Rear Suspension: Single shock; 2.8-in. travel Front & Rear Tire: 2.50-10-4PR Wheelbase 36.4 in. Fuel Capacity 0.8 gal. The TT-R50E is a dream come ...

A team of four D.C. real estate agents who’ve listed and sold some of the D.C.-area’s most high-profile, multimillion-dollar homes has moved their shingle to TTR Sotheby’s after years of ...

Relative increases in serum TTR concentrations resulting from greater ... CVH events relative to placebo at Month 30, as well as a 50% reduction in the cumulative frequency of CVH events relative ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval ...